Jia Shen
Cardiovascular Disease · San Diego, CANPI 1295053403
Payments from drug & device makers
Across 100 payments — averaging $348.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Quidel Corporation$32K
- Impulse Dynamics (USA) Inc.$468
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$440
- Philips North America LLC$322
- Novartis$311
- Amgen$189
- plus $1K from 18 others
Across 9 payments — averaging $6416.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$58K
What the payments were for
- Food & beverage$3,069100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Quidel Corporation | 8 | $31,725 |
| Impulse Dynamics (USA) Inc. | 3 | $468 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $440 |
| Philips North America LLC | 7 | $322 |
| Novartis | 18 | $311 |
| Amgen | 11 | $189 |
| Boehringer Ingelheim | 9 | $183 |
| Biotronik Inc. | 2 | $137 |
| Abbott | 2 | $124 |
| Braemar Manufacturing, LLC | 1 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $116 |
| Boston Scientific | 3 | $108 |
| Medtronic | 1 | $94 |
| Kestra Medical Technology Services, Inc. | 2 | $90 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Scpharmaceuticals Inc. | 2 | $51 |
| Pfizer | 3 | $48 |
| Irhythm Technologies, Inc. | 2 | $37 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$936
- LifeVest$234
- (5050) Extended Holter$136
- Cardiac Monitoring Suite$122
- PRALUENT$116
- Acticor$112
- Solia$112
- Edora$112
- BioMonitor$112
- Rivacor$112
- CARDIOMEMS$103
How this compares
$34,806 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 275 | $355,605 |
| JardianceEmpagliflozin | 86 | $111,821 |
| EntrestoSacubitril/Valsartan | 82 | $111,812 |
| Repatha SureclickEvolocumab | 141 | $97,439 |
| XareltoRivaroxaban | 63 | $95,838 |
| OzempicSemaglutide | 48 | $52,274 |
| Praluent PenAlirocumab | 66 | $41,268 |
| MultaqDronedarone Hcl | 24 | $19,901 |
| Repatha SyringeEvolocumab | 21 | $15,923 |
| BrilintaTicagrelor | 11 | $12,385 |
| Repatha PushtronexEvolocumab | 13 | $9,733 |
| Rosuvastatin Calcium | 401 | $9,045 |
| Metoprolol Succinate | 530 | $7,763 |
| Atorvastatin Calcium | 450 | $4,800 |
| Ezetimibe | 120 | $4,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $355,605275 claims |
| Boehringer IngelheimJardiance | $183 | $111,82186 claims |
| NovartisEntresto | $311 | $111,81282 claims |
| Johnson & JohnsonXarelto | $19 | $95,83863 claims |
| Sanofi-aventis U.S. LLCMultaq | $116 | $19,90124 claims |
| AstraZenecaBrilinta | $20 | $12,38511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$10.2M
- Michael WilkinsonSan Diego$1.9M
- William PennySan Diego$829K
- Ajit RaisinghaniSan Diego$695K
- Kevin KingSan Diego$598K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.